NCT02443545

Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 134 (actual)
• Sponsor: ApoPharma · Industry
• Sex: All
• Age: 3 Years
• Healthy volunteers: Not accepted

Summary

This is a long-term follow-up to an earlier study, LA38-0411. Its purpose is to gather more information about the safety and efficacy of deferiprone in patients with sickle cell disease or other anemias who suffer from iron overload caused by regular blood transfusions.

Detailed description

Deferiprone (brand name Ferriprox®) is an iron chelator that is approved in the United States and over 60 other countries for the treatment of iron overload in patients with thalassemia, when other treatments are inadequate. This study has been designed to evaluate the long-term efficacy, safety, and tolerability of deferiprone to treat iron overload in patients who have sickle cell disease or other anemias. Only patients who have completed an earlier study, LA38-0411, are eligible to enroll in this one.

Conditions

• Iron Overload
• Sickle Cell Disease
• Other Anemias

Interventions

Type	Name	Description
DRUG	Deferiprone

Timeline

• Start date: 2015-05-21
• Primary completion: 2019-04-30
• Completion: 2019-08-21
• First posted: 2015-05-14
• Last updated: 2024-01-10
• Results posted: 2024-01-10

Locations

13 sites across 5 countries: United States, Canada, Egypt, Saudi Arabia, United Kingdom